- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01001936
Study Evaluating SKI-606 in Subject With Solid Tumors
October 26, 2009 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Does-escalation Study of Oral SKI-606 in Subjects With Advanced Malignant Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of oral SKI-606 (100, 200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.
This study will also obtain preliminary information on the pharmacokinetics and antitumor activity of orally administered SKI-606 in subjects with advanced malignant solid tumors
Study Overview
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 74 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Advanced or recurrent solid malignancy confirmed histologically or cytologically for which no effective therapy is available
- Recovery from acute adverse effects of prior therapies to £ Grade 1 (excluding alopecia)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
- Adequate hepatic, renal, and bone marrow function
- Age 20 to 74 years
- Willingness of male and female subjects, who are not surgically sterile or postmenopausal, to use reliable methods of birth control for the duration of the study and for 6 months and 30 days after the last dose of test article for male and female, respectively
- Life expectancy of at least 12 weeks
Exclusion Criteria:
- Use of any systemic antitumor agents or any investigational agent within 28 days before the enrollment (42 days if the previous chemotherapy included nitrosoureas or mitomycin C)
- Ongoing clinical requirement for administration of a strong inhibitor of CYP3A4
- Prior exposure to SKI-606 or any other Src-kinase inhibitor
- Major surgery or radiotherapy within 2 weeks before the enrollment (recovery from previous surgery should be complete before day 1)
- Subjects unable or unwilling to swallow SKI-606 capsules
- Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth
- Recent or ongoing clinically-significant gastrointestinal disorder
- Pregnant or breastfeeding women
Subjects who meet the following criteria:
- Evidence of serious active infection, significant medical or psychiatric illness
- History of unexplained syncope or known ventricular arrythmia
- Known seropositivity to HIV, or current or chronic Hepatitis B or Hepatitis hepatitis C
- Hypokalemia
- Unstable concurrent medical conditions
- Any other condition that, in the investigator's judgment, make the subject inappropriate for this study the subject inappropriate for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety as measured by AE information. Tolerability as measured by DLT observation.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics as measured by Taylor Technology Antitumor activity as measured by RECIST
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
October 26, 2009
First Submitted That Met QC Criteria
October 26, 2009
First Posted (Estimate)
October 27, 2009
Study Record Updates
Last Update Posted (Estimate)
October 27, 2009
Last Update Submitted That Met QC Criteria
October 26, 2009
Last Verified
October 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3160A1-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
AmgenCompletedSolid Tumors | Oncology | Tumors
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedCancer | Advanced Solid Tumors | TumorsUnited States
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
OncoMed Pharmaceuticals, Inc.CompletedRefractory Solid Tumors | Advanced Relapsed TumorsUnited States
Clinical Trials on SKI-606
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); PfizerTerminatedChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 30 Percent of Peripheral Blood White CellsUnited States
-
Massachusetts General HospitalPfizer; Dana-Farber Cancer Institute; Brigham and Women's HospitalCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedHealthy SubjectsUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedHealthyUnited States
-
PfizerCompletedBreast Neoplasms | Neoplasm MetastasisUnited States, Ukraine, Russian Federation, Hong Kong, France, Australia, Poland, Malta
-
PfizerCompletedPhiladelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)Singapore
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
PfizerCompletedChronic Myeloid LeukemiaUnited States, Spain, Australia, Canada, Hong Kong, Singapore, United Kingdom, Germany, Netherlands, Chile, India, South Africa, Sweden, Peru, Argentina, Italy, Austria, Colombia, Brazil, China, Finland, Hungary, Korea, Republic of, M... and more